Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Kaufen / Verkaufen

Top-Partner CFD-Broker

Plus500
  • Keine Kommissionen, enge Spreads
  • Hebel- und Long/Short-Trading, fortgeschrittene Analysetools, kostenlose Echtzeitkurse etc.
  • CFD-Trading auf Aktien, Indizes, Krypto, Rohstoffe und Devisen
Direkt zu Plus500 CFD service. Ihr Kapital unterliegt einem Risiko.

Premium-Partner

IG Bank
  • Ein weltweit führender CFD-Anbieter*, FINMA-reguliert
  • Über 17'000 Märkte: Indizes, Devisen, Rohstoffe, Aktien, Kryptowährungen, Optionen und mehr
  • Erweiterte Handelszeiten und Wochenendhandel
  • Schweizer Kundenserviceteam, mit Büros in Genf und Zürich
*Die IG Gruppe ist grösster Anbieter nach Umsatz (veröffentlichter Geschäftsbericht 2022)
Direkt zur IG Bank Verluste können Einlagen übersteigen.
Saxo Bank
  • Lizenzierte Schweizer Bank (FINMA)
  • Keine Depotgebühren bei aktivierter Wertpapierleihe
  • Aktien, ETFs, Optionen, FX, CFDs, Futures, Rohstoffe, Bonds, Mutual Funds - auf einer Plattform
  • Gratis Expertenanalysen und Trading-Signale
  • Saxo Deal: Rückerstattung der Courtagen bis CHF 200 während 90 Tagen
Direkt zur Saxo Bank
Werbung
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
18.12.2024 18:00:00

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

Gensight Biologics
0.30 EUR -5.85%
Kaufen / Verkaufen

Regulatory News:

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided an update on its regulatory discussions with the French medicines safety agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé or the ANSM) and on its financial strategy.

Ongoing Discussions with the ANSM

The Company confirms the continuation of a constructive and collaborative communication with the ANSM on the updated regulatory file for LUMEVOQ® submitted in November. These discussions demonstrate mutual commitment to advancing toward the resumption of the Early Access Program in France (Autorisation d’Accès Compassionnel or AAC) for the Company’s gene therapy LUMEVOQ®.

Operational Readiness

GenSight Biologics has completed all preparations to supply LUMEVOQ® to the treatment center at the 15-20 National Hospital in Paris, which will optimize the time to the first injections after receipt of regulatory acceptance from the ANSM. Both the Company and the 15-20 National Hospital are aware of the acute need for treatment among eligible Leber Hereditary Optic Neuropathy (LHON) patients who have been waiting for the AAC program to resume. The first patient injections are now expected in January 2025, instead of late December as previously announced.

Financial Strategy

The Company does not have sufficient net working capital to meet its obligations over the next 12 months but only until early January 2025. The Company is currently engaged in advanced discussions to secure financing for its activities until the end of January 2025. The Company expects to receive the first payments from the resumption of the AAC Program at the end of January 2025, which would extend its cash runway beyond 12 months.

Share Information

As of today, the share capital of GenSight Biologics is composed of 117,517,544 ordinary shares.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics’ regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.

Nachrichten zu Gensight Biologics SA

  • Relevant
  • Alle
  • vom Unternehmen
  • ?
Keine Nachrichten verfügbar.

Analysen zu Gensight Biologics SA

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien im BX Musterportfolio📈: Palo Alto Networks, Fiserv & Motorola Solutions

Im BX Morningcall werden folgende Aktien analysiert und erklärt:

✅ Motorola Solutions
✅ Fiserv Inc.
✅ Palo Alto Networks

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien im BX Musterportfolio📈: Palo Alto Networks, Fiserv & Motorola Solutions mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’129.73 19.42 BCASMU
Short 12’374.41 13.87 S2S3XU
Short 12’853.64 8.76 UMBS6U
SMI-Kurs: 11’640.13 18.12.2024 17:30:00
Long 11’155.84 19.10 SSZMHU
Long 10’895.92 13.55 SSQMTU
Long 10’460.66 8.96 3SSMZU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten